Iovance Biotherapeutics, Inc.
NASDAQ:IOVABiotechnology
-$0.04 today
- Market cap
- $3.46B
- Beta
- 0.70
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.85
Volume 6.99M
Average 14.09M
IOVA Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Iovance Biotherapeutics, Inc.NASDAQ: IOVA
Operating Expenses · Q3 FY2026 · quarter ended Sep 2026
Operating expenses declines year over year
Q3 FY2026 operating expenses of $97.41M fell 18.0% year over year, behind the -11.1% change in trailing-twelve-month operating expenses. Sequentially, it fell 9.5% from the prior quarter. Over 3 fiscal years it compounded at +7.0% a year.
Context
- Operating expenses amounted to 185.4% of revenue in FY2025, down 79.9 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -18.0% toward the trailing-twelve-month pace of -11.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 488.53M USD
- Year-over-year change
- +12.2%
- 4-year CAGR
- +9.3%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 488.53M | +12.2% |
| FY2024 | 2024-12-31 | 435.35M | -3.5% |
| FY2023 | 2023-12-31 | 450.99M | +13.1% |
| FY2022 | 2022-12-31 | 398.88M | +16.4% |
| FY2021 | 2021-12-31 | 342.7M | — |
Operating Expenses vs competitors
How IOVA compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -11.1% is the 7th highest of 10, against a peer median of +8.6%.
- Operating expenses amounts to 114.0% of revenue for IOVA, versus a peer median of 142.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €3.77B EUR | +18.8% | +18.2% | 142.6% | |
| LTM Jun 2026 | $2.51B USD | — | -36.0% | 60.7% | |
| LTM Sep 2026 | $740.02M USD | -0.1% | +14.3% | 54.5% | |
| LTM Sep 2026 | $450.66M USD | +32.9% | +1.6% | 246.8% | |
| LTM Sep 2026 | $432.13M USD | -11.1% | +7.0% | 114.0% | |
| LTM Mar 2026 | $410.51M USD | +8.6% | +21.4% | 106.4% | |
| LTM Dec 2025 | $325.61M USD | +35.1% | +30.8% | — | |
| LTM Sep 2026 | $299.94M USD | +54.6% | +80.8% | — | |
| LTM Mar 2026 | $113.16M USD | -11.7% | -28.7% | 1791.7% | |
| LTM Mar 2026 | $91.02M USD | -33.2% | -6.5% | — | |
| LTM Mar 2026 | $51.84M USD | -32.4% | +34.1% | 5184.4% | |
| Peer median (excluding IOVA) | — | +8.6% | +16.3% | 142.6% | |
Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.19M | 164.07M | 263.5M |
| Cost of Revenue | 0 | 0 | 10.76M | 124M | 173.18M |
| Gross Profit | 0 | 0 | (9.57M) | 40.08M | 90.32M |
| Gross Margin | — | — | -804.5% | 24.4% | 34.3% |
| Research & Development | 259.04M | 294.78M | 344.08M | 282.34M | 300.27M |
| Selling, General & Admin | 83.66M | 104.1M | 106.92M | 153.02M | 152.32M |
| Operating Expenses | 342.7M | 398.88M | 450.99M | 435.35M | 488.53M |
| Depreciation & Amortization | 13.98M | 21.14M | 33.13M | 43.61M | 47.32M |
| EBITDA | (328.27M) | (371.77M) | (414.39M) | (331.4M) | (350.89M) |
| EBITDA Margin | — | — | -34851.9% | -202.0% | -133.2% |
| Operating Income | (342.7M) | (398.88M) | (460.56M) | (395.28M) | (398.21M) |
| Operating Margin | — | — | -38735.0% | -240.9% | -151.1% |
| Interest Income | 451K | 2.99M | 13.04M | 20.27M | 10.31M |
| Interest Expense | 0 | 2.99M | 0 | 0 | 0 |
| Other Income / Expenses | 451K | 2.99M | 13.04M | 20.27M | 5.16M |
| Income Before Tax | (342.25M) | (395.89M) | (447.52M) | (375.01M) | (393.05M) |
| Pre-Tax Margin | — | — | -37638.0% | -228.6% | -149.2% |
| Income Tax Expense | 0 | 0 | (3.48M) | (2.83M) | (2.07M) |
| Net Income | (342.25M) | (395.89M) | (444.04M) | (372.18M) | (390.98M) |
| Net Margin | — | — | -37345.4% | -226.8% | -148.4% |
| EPS (Basic) | (2.23) | (2.49) | (1.89) | (1.28) | (1.09) |
| EPS (Diluted) | (2.23) | (2.49) | (1.89) | (1.28) | (1.09) |
| Weighted Avg Shares | 153.41M | 159.26M | 235.13M | 289.88M | 357.35M |
| Weighted Avg Shares (Diluted) | 153.41M | 159.26M | 235.13M | 289.88M | 357.35M |
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
Intrinsic Alpha fair value
Locked
Current Price
$7.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.